CALIMMUNE
Calimmune is a clinical-stage gene therapy company. The company’s lead therapeutic candidate, is a gene-based therapy engineered to control HIV infection and to protect individuals with HIV from progressing to AIDS. The therapy is currently being evaluated in Phase I/II studies. Cal-1 is designed to reduce production of CCR5, a protein on the surface of white blood cells that plays a critical role in enabling HIV to infect cells. It also has a second mechanism aimed at preventing viral fusion, the process by which the virus enters the cell. This dual approach was shown to be effective against broad strains of HIV in pre-clinical studies.
CALIMMUNE
Industry:
Biotechnology Genetics Health Care Medical Therapeutics
Founded:
2006-01-01
Address:
Pasadena, California, United States
Country:
United States
Website Url:
http://www.calimmune.com
Total Employee:
1+
Status:
Active
Contact:
(619) 849-5375
Email Addresses:
[email protected]
Total Funding:
15.85 M USD
Technology used in webpage:
Viewport Meta Font Awesome Mobile Non Scaleable Content Pound Sterling Starfield Technologies Sucuri Cloudproxy ATT DNS
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Atara Biotherapeutics
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
BirchBioMed
BirchBioMed is a clinical-stage biomedical company.
Bolder BioTechnology
Bolder BioTechnology, Inc. is a clinical stage protein therapeutics company.
Cellenkos
Cellenkos is a clinical stage biotech company.
Cure Forward
Cure Forward helps cancer patients and physicians access advanced treatments in oncology.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Juno Therapeutics
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
Rion
RION is a clinical-stage regenerative medicine company.
Sirenas Marine Discovery
A Biomedical research organization
Virometix
Virometix is a privately held biotechnology company developing
WeGene
WeGene is a genetic testing and personalized healthcare service provider company.
CareDx
CareDx is a novel molÂeÂcÂuÂlar diagnosÂtics comÂpany.
Current Advisors List
Current Employees Featured
Founder
Investors List
Alexandria Venture
Alexandria Venture investment in Series B - Calimmune
Translational Accelerator
Translational Accelerator investment in Series B - Calimmune
RA Capital Management
RA Capital Management investment in Series B - Calimmune
Official Site Inspections
http://www.calimmune.com
- Host name: cloudproxy10005.sucuri.net
- IP address: 192.124.249.5
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Calimmune"
Calimmune - Crunchbase Company Profile & Funding
May 27, 2015 Calimmune may be growing as indicated by the sale of the company to CSL Behring, which suggests a successful exit and a likely increase in resources and capabilities. The company's leadership, consisting of …See details»
CSL Behring Acquires Biotech Company Calimmune and its …
About Calimmune: Calimmune is a privately owned company committed to accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases. To …See details»
Calimmune Company Profile 2024: Valuation, Investors …
Calimmune General Information Description. Developer of a gene modification and cell delivery technology based in Tucson, Arizona. The company's technology works by genetically modifying patients' own cells to shield and strengthen …See details»
CSL Behring to Acquire Biotech Company Calimmune …
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform. Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a …See details»
CSL Behring buys Calimmune for early stem cell, gene …
Aug 28, 2017 Calimmune’s chief, Louis Breton, added: “We are excited to become part of CSL Behring. They are an established global industry leader in protein-replacement therapies and have a proven track ...See details»
CALIMMUNE, INC. Company Profile | Pasadena, CA | Competitors ...
Find company research, competitor information, contact details & financial data for CALIMMUNE, INC. of Pasadena, CA. Get the latest business insights from Dun & Bradstreet.See details»
Calimmune, Inc. - LinkedIn
Calimmune, Inc. | 736 followers on LinkedIn. Calimmune was founded in 2006 based on breakthrough gene modification and cell delivery technology developed in the labs of Nobel Laureate David ...See details»
CSL Behring pays $91M upfront for early stage gene therapy
Aug 30, 2017 CSL Behring has bought out Calimmune, a Tucson-based stem cell gene therapy biotech, for a $91 million upfront payment. The deal gives CSL Behring access to …See details»
Tucson's Calimmune to be acquired by Australian drug giant
Aug 29, 2017 Calimmune Inc., a gene-therapy drug startup company co-founded by a University of Arizona alumnus, will be acquired by Australian-based biotech drug giant CSL Ltd. for $91 …See details»
Expanding Cell- and Gene-Therapy Capability in the …
The original lab and office space at the Hill site became part of CSL Behring in 2017 upon the acquisition of Calimmune Inc. From 2018 to 2019, the Good Manufacturing Practice (GMP) cell manufacturing facility and two additional …See details»
CSL Behring to Acquire Biotech Company Calimmune …
Aug 28, 2017 Calimmune's lead development programs are novel ex vivo gene therapies for hematologic diseases. About CSL Behring CSL Behring is a global biotherapeutics leader driven by its promise to save lives.See details»
Calimmune - Products, Competitors, Financials, Employees, …
Calimmune is developing a full product pipeline of therapeutic candidates to address the unique needs of individuals at different stages of HIV infection and with various treatment histories. …See details»
CSL buys stem cell therapy firm Calimmune | SBS News
Aug 28, 2017 The acquisition will provide CSL Behring, CSL's blood products business, with Calimmune's haematopoietic stem cell gene therapy which is being developed for the …See details»
Calimmune - VentureRadar
Calimmune's lead product candidate for HIV, now in Phase I/II studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. Calimmune is developing a full …See details»
Sickle Cell Disease Therapies May Get Boost from CSL Behring's...
Sep 7, 2017 Calimmune “has built a robust technology platform, and designed a promising HSC gene therapy candidate, CAL-H, which strongly aligns with our longer-term strategic goals, …See details»
The Arizona Bioscience Company of the Year is on a Mission to …
Calimmune, Inc., acquired by global biotechnology leader CSL Limited in 2017 and now fully integrated within CSL, to be honored as the Arizona Bioscience Company of the Year at the …See details»
HIV biotech Calimmune bags $15M to move one-time gene
May 27, 2015 After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene …See details»
Calimmune Approved to Treat Second Group in HIV Stem Cell …
Calimmune is a clinical-stage HIV gene medicine company focused on developing innovative cell-based therapies for HIV. The company’s stem cell technology was discovered in the labs of …See details»
Calimmune Expands Lentiviral Gene Therapy Pipeline Through
Dec 5, 2016 TUCSON, Ariz.--(BUSINESS WIRE)--Calimmune, Inc., a clinical-stage gene therapy company, today announced a license agreement with Cincinnati Children’s Hospital …See details»
CalImmune Cleared to Move HIV Drug into Next Cohort in Phase …
Jul 3, 2014 CalImmune was founded to develop a method for preventing HIV infection from progressing to AIDS by knocking down CCR5, a chemokine receptor used by HIV as a co …See details»